Peptide Hydrogel for Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 In Vitro

Overview

Journal J Funct Biomater

Specialty Biomedical Engineering

Date 2024 Dec 27

PMID 39728169

Authors

Dalin Wang

Guangyan Qi

Mingcai Zhang

Brandon Carlson

Matthew Gernon

Douglas Burton

Xiuzhi Susan Sun

Jinxi Wang

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the impact of varying the formulation of a specific peptide hydrogel (PepGel) on the release kinetics of rhBMP-2 in vitro. Three PepGel formulations were assessed: (1) 50% / (peptides volume/total volume) PepGel, where synthetic peptides were mixed with crosslinking reagents and rhBMP-2 solution; (2) 67% / PepGel; (3) 80% / PepGel. Each sample was loaded with 12 µg of rhBMP-2 and incubated in PBS. Released rhBMP-2 was quantified by ELISA at 1 h, 6 h, and 1, 2, 4, 7, 10, 14, and 21 days. To explore how PepGel formulations influence rhBMP-2 release, the gel porosities, swelling ratios, and mechanical properties of the three PepGel formulations were quantitatively analyzed. The results showed that rhBMP-2 encapsulated with 50% / PepGel exhibited a sustained release over the 21-day experiment, while the 67% and 80% / PepGels demonstrated significantly lower rhBMP-2 release rates compared to the 50% formulation after day 7. Higher histological porosity of PepGel was significantly correlated with increased rhBMP-2 release rates. Conversely, the swelling ratio and elastic modulus of the 50% / PepGel were significantly lower than that of the 67% and 80% / formulations. In conclusion, this study indicates that varying the formulation of crosslinked PepGel can control rhBMP-2 release rates in vitro by modulating gel porosity, swelling ratio, and mechanical properties. Encapsulation with 50% / PepGel offers a sustained rhBMP-2 release pattern in vitro; if replicated in vivo, this could mitigate the adverse effects associated with burst release of rhBMP-2 in clinical applications.

References

Liang J, Liu G, Wang J, Sun X . Controlled release of BSA-linked cisplatin through a PepGel self-assembling peptide nanofiber hydrogel scaffold. Amino Acids. 2017; 49(12):2015-2021. DOI: 10.1007/s00726-017-2444-z. View

Dickerman R, Reynolds A, Morgan B, Tompkins J, Cattorini J, Bennett M . rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys!. Spine J. 2007; 7(4):508-9. DOI: 10.1016/j.spinee.2007.03.003. View

Toth J, Boden S, Kenneth Burkus J, Badura J, Peckham S, McKay W . Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976). 2009; 34(6):539-50. DOI: 10.1097/BRS.0b013e3181952695. View

Balakrishnan B, Banerjee R . Biopolymer-based hydrogels for cartilage tissue engineering. Chem Rev. 2011; 111(8):4453-74. DOI: 10.1021/cr100123h. View

Yasen M, Li X, Jiang L, Yuan W, Che W, Dong J . Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis. J Orthop Res. 2015; 33(9):1297-304. DOI: 10.1002/jor.22763. View

Boden S . The biology of posterolateral lumbar spinal fusion. Orthop Clin North Am. 1998; 29(4):603-19. DOI: 10.1016/s0030-5898(05)70034-1. View

Wong D, Kumar A, Jatana S, Ghiselli G, Wong K . Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2007; 8(6):1011-8. DOI: 10.1016/j.spinee.2007.06.014. View

Brower R, Vickroy N . A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine (Phila Pa 1976). 2008; 33(18):E653-5. DOI: 10.1097/BRS.0b013e31817c4f1c. View

Meng B, Bunch J, Burton D, Wang J . Lumbar interbody fusion: recent advances in surgical techniques and bone healing strategies. Eur Spine J. 2020; 30(1):22-33. DOI: 10.1007/s00586-020-06596-0. View

10.

Hsu W, Polavarapu M, Riaz R, Larson A, Diegmueller J, Ghodasra J . Characterizing the host response to rhBMP-2 in a rat spinal arthrodesis model. Spine (Phila Pa 1976). 2013; 38(12):E691-8. DOI: 10.1097/BRS.0b013e31828cb977. View

11.

Ikeno M, Hibi H, Kinoshita K, Hattori H, Ueda M . Effects of self-assembling peptide hydrogel scaffold on bone regeneration with recombinant human bone morphogenetic protein-2. Int J Oral Maxillofac Implants. 2013; 28(5):e283-9. DOI: 10.11607/jomi.te09. View

12.

Bertz A, Wohl-Bruhn S, Miethe S, Tiersch B, Koetz J, Hust M . Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: influence of network structure and drug size on release rate. J Biotechnol. 2012; 163(2):243-9. DOI: 10.1016/j.jbiotec.2012.06.036. View

13.

McClellan J, Mulconrey D, Forbes R, Fullmer N . Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006; 19(7):483-6. DOI: 10.1097/01.bsd.0000211231.83716.4b. View

14.

Qiang L, Fan M, Wang Y, Liu Y, Zhuang H, Guo R . Injectable hydrogel loaded with bilayer microspheres to inhibit angiogenesis and promote cartilage regeneration for repairing growth plate injury. Front Bioeng Biotechnol. 2023; 11:1181580. PMC: 10232875. DOI: 10.3389/fbioe.2023.1181580. View

15.

Zhang X, Yu Q, Wang Y, Zhao J . Dose reduction of bone morphogenetic protein-2 for bone regeneration using a delivery system based on lyophilization with trehalose. Int J Nanomedicine. 2018; 13:403-414. PMC: 5769568. DOI: 10.2147/IJN.S150875. View

16.

Verma V, Verma P, Kar S, Ray P, Ray A . Fabrication of agar-gelatin hybrid scaffolds using a novel entrapment method for in vitro tissue engineering applications. Biotechnol Bioeng. 2006; 96(2):392-400. DOI: 10.1002/bit.21111. View

17.

Altunbas A, Lee S, Rajasekaran S, Schneider J, Pochan D . Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles. Biomaterials. 2011; 32(25):5906-14. PMC: 3119512. DOI: 10.1016/j.biomaterials.2011.04.069. View

18.

Wildemann B, Kadow-Romacker A, Lubberstedt M, Raschke M, Haas N, Schmidmaier G . Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier. Calcif Tissue Int. 2004; 76(1):50-5. DOI: 10.1007/s00223-004-0040-1. View

19.

Basu S, Pacelli S, Feng Y, Lu Q, Wang J, Paul A . Harnessing the Noncovalent Interactions of DNA Backbone with 2D Silicate Nanodisks To Fabricate Injectable Therapeutic Hydrogels. ACS Nano. 2018; 12(10):9866-9880. PMC: 6563937. DOI: 10.1021/acsnano.8b02434. View

20.

Koerner J, Markova D, Schroeder G, Calio B, Shah A, Brooks C . The local cytokine and growth factor response to recombinant human bone morphogenetic protein-2 (rhBMP-2) after spinal fusion. Spine J. 2018; 18(8):1424-1433. DOI: 10.1016/j.spinee.2018.03.006. View